The TKD modification ensured the selective delivery of doxorubicin-containing micelles to human breast cancer MCF-7 cells expressing HSP70 on their plasma membrane; this TKD-mediated selective targeting was accompanied by an increased uptake of the drug-loaded micelles and retarded proliferation in the treated MCF-7 cells. The gene discussed is HSPA1A; the disease is breast carcinoma.